NCT05905913 - FiH Study to Assess Safety and PK of SAD and MAD of ANT3310 Alone and in Combination With Meropenem in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 12, 2023

Primary Completion Date

January 5, 2024

Study Completion Date

January 5, 2024

Conditions

Healthy Volunteers

Interventions

DRUG

ANT3310

ANT3310 will be infused over 3 hours

DRUG

ANT3310-placebo

ANT3310-placebo will be infused over 3 hours

DRUG

ANT3310

ANT3310 will be infused over 3 hours every 8 hours

DRUG

ANT3310-placebo

ANT3310-placebo will be infused over 3 hours every 8 hours

DRUG

ANT3310-placebo

ANT3310-placebo will be infused over 3 hours as a single dose as part of the drug drug interaction study, then every 8 hours as part of the repeat doses study.

DRUG

ANT3310

ANT3310 will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.

DRUG

Meropenem

Meropenem will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.

DRUG

Meropenem-placebo

Meropenem-placebo will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.

Trial Locations (1)

35042

Biotrial, Rennes